about
Quality of life in Parkinson's diseaseAnxiety in Parkinson's disease: identification and managementAffect-modulated startle: interactive influence of catechol-O-methyltransferase Val158Met genotype and childhood trauma.The neurobiology of social phobia: from pharmacotherapy to brain imaging.Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR).Treatment of Depression in the Patient with Parkinson's Disease.Parkinson's disease as a disconnection syndromeParkinson's disease: the quintessential neuropsychiatric disorderBupropion-SR in treatment of social phobia.Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse.Frequency of social phobia and psychometric properties of the Liebowitz social anxiety scale in Parkinson's disease.Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI.Parkinson's disease and anxietyBehavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.Does anxiety cause freezing of gait in Parkinson's disease?Depression in Parkinson's disease -- a review.Psychiatric symptoms in Parkinson's disease.A qualitative analysis of mindfulness-based cognitive therapy (MBCT) in Parkinson's disease.Plant-derived flavanol (-)epicatechin mitigates anxiety in association with elevated hippocampal monoamine and BDNF levels, but does not influence pattern separation in mice.Behavioral changes associated with deep brain stimulation surgery for Parkinson's disease.Behavioral disturbances in Parkinson's diseaseRange of neuropsychiatric disturbances in patients with Parkinson's disease.Impact of anxiety on quality of life in Parkinson's disease.Neurocognitive correlates of apathy and anxiety in Parkinson's disease.Anxiety and medical disorders.Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.Recognition and management of neuropsychiatric complications in Parkinson's disease.Mood fluctuations in Parkinson's disease: a pilot study comparing the effects of intravenous and oral levodopa administration.Specific impairments in the recognition of emotional facial expressions in Parkinson's disease.Parkinson's disease without tremor masquerading as mechanical back pain; a case report.Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study.Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity.A smaller amygdala is associated with anxiety in Parkinson's disease: a combined FreeSurfer-VBM study.Depression in Parkinson's disease. Pharmacological characteristics and treatment.Cognitive-behavioral treatment for social phobia in Parkinson's disease: A single-case studyBehind the mask : a study on the clinical course, psychopathology and impact on quality of life in idiopathic Parkinson's disease.Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis.Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine.
P2860
Q26849637-86301271-41CD-42BA-A538-26D8E0717221Q27020996-8792755C-FF29-48CD-9D27-3653FE14E2FBQ28728111-5CFEC1BA-B2FE-427D-89B2-3D9846435924Q31837126-E601865C-065A-4451-BE67-26877E0AAC10Q33609711-BE8EB211-85C3-4E1B-AADB-3D6A0046393EQ33704127-19B19BDD-600D-4702-80A3-ADF7FBA97708Q33901047-D9378A1D-A1AC-453C-9367-45527C944ACFQ33917094-962F62AB-8F0D-4005-AA26-2181CF4AE00DQ33926160-76B23A03-2436-481E-B600-D9A827D4369EQ33987540-B1EEA2C0-ECD4-49AA-BD37-064FEFCAD8A3Q34013056-4ECB2912-0DB8-4B8A-B616-33F2DA504073Q34075089-B785838E-53D5-486E-9218-5C6463CDB6D7Q34132060-CE35ED28-02AE-4BA4-A2D3-856005949539Q34192760-6AD1C47D-4911-4A00-B612-90DECA58DF52Q34243678-FD50378E-3C0B-4116-B981-DF4EC46236C2Q34478301-900A61EA-C33C-43DC-A30A-846F667B2651Q34666435-669CC09B-F241-46F8-8DD9-61A4CFFBAE52Q35008710-4AFCFE7A-1140-4378-8D73-5F05932BB636Q35034790-5774B566-1D36-4032-804B-77ADDA4A8855Q35203991-74974C44-5F01-4197-8150-FABCE2443168Q35236819-200A0527-B4BC-4745-929C-E2C303F8B4D0Q35453530-83BFFC21-6E69-481B-9569-F0C0E674C9C0Q35609023-A8038657-1AED-4ECE-881C-A3C18024128FQ35615127-6A3EDA41-41DE-4CC8-8504-669196F97028Q36228200-181DE57E-D75B-416F-A52D-3308114BEA5FQ36603634-ACC86BB7-EF31-47EE-B833-407922CCC45EQ36673715-AE506B78-7AF1-4F18-897F-5214B7F68AE6Q36703819-C6FF346E-7F27-48E7-87E5-FC1A74D091FCQ36800921-FE87CFAB-5F56-42E2-833E-FCA13D723785Q36859627-CE900F6C-1E17-4151-9491-A0D14FAFB98AQ37187592-72B2A951-7330-46CD-9685-CD90A1840EAEQ37771075-85580F24-BE43-41D8-9581-19AF9E22C299Q37811038-D999F232-FE3A-49BF-9AC1-02C46E517772Q38792540-2303BA44-2839-49A3-899C-1D15CC08FC50Q39005374-D6586572-AD20-4B1E-BE7C-0896828B4697Q39450868-AD8DDB21-1CD4-4B91-927B-EC585E54F7A1Q42412741-7732D99E-473F-4A07-8270-E02B223561D6Q42413314-EAD3AD6D-4259-4D8F-B488-4AA4B49E5C90Q42594853-5DA23E48-E7AE-46A7-96F1-6D60D634EF64Q43248205-A75D74A3-2983-47E6-8330-918C69233CDF
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Anxiety and Parkinson's disease.
@en
type
label
Anxiety and Parkinson's disease.
@en
prefLabel
Anxiety and Parkinson's disease.
@en
P2093
P356
P1476
Anxiety and Parkinson's disease.
@en
P2093
P304
P356
10.1176/JNP.8.4.383
P577
1996-01-01T00:00:00Z